BRAFV600E mutation, which is the most common oncogenic genetic event found in thyroid cancer, particularly in PTC, results in constitutive and oncogenic activation of BRAF kinase in the MAPK signaling pathway [10]. This evidence concerns the gene BRAF and thyroid gland carcinoma.